127 related articles for article (PubMed ID: 26391423)
1. Interferon-Free Sofosbuvir-Based Anti-HCV Therapy After Liver Transplantation.
Seifert LL; Vorona E; Bester C; Stahl M; Hüsing A; Beckebaum S; Kabar I; Heinzow H; Schmidt HH
Ann Transplant; 2015 Sep; 20():561-8. PubMed ID: 26391423
[TBL] [Abstract][Full Text] [Related]
2. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
Ciesek S; Proske V; Otto B; Pischke S; Costa R; Lüthgehetmann M; Polywka S; Klempnauer J; Nashan B; Manns MP; von Hahn T; Lohse AW; Wedemeyer H; Mix H; Sterneck M
Transpl Infect Dis; 2016 Jun; 18(3):326-32. PubMed ID: 26988272
[TBL] [Abstract][Full Text] [Related]
4. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
Lionetti R; Calvaruso V; Piccolo P; Mancusi RL; Mazzarelli C; Fagiuoli S; Montalbano M; Lenci I; Carrai P; Guaraldi G; Visco-Comandini U; Milana M; Biolato M; Loiacono L; Valente G; Craxì A; Angelico M; D'offizi G
Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29193356
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data.
Pyrsopoulos N; Trilianos P; Lingiah VA; Fung P; Punnoose M
Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):761-765. PubMed ID: 29481384
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of low accelerating dose regimen of interferon/ribavirin antiviral therapy in patients with hepatitis C virus recurrence after liver transplantation.
Su H; Liu Z; Sun Y; Li H; Zhou S; Zhou X; Gao Y; Tang R; Zhang D; Zhang M
Ann Transplant; 2015 May; 20():263-8. PubMed ID: 25975740
[TBL] [Abstract][Full Text] [Related]
7. Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
Campos-Varela I; Moreno A; Morbey A; Guaraldi G; Hasson H; Bhamidimarri KR; Castells L; Grewal P; Baños I; Bellot P; Brainard DM; McHutchison JG; Terrault NA
Aliment Pharmacol Ther; 2016 Jun; 43(12):1319-29. PubMed ID: 27098374
[TBL] [Abstract][Full Text] [Related]
8. Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.
Donato MF; Morelli C; Romagnoli R; Invernizzi F; Mazzarelli C; Iemmolo RM; Montalbano M; Lenci I; Bhoori S; Pieri G; Berardi S; Caraceni P; Martini S;
Liver Int; 2017 May; 37(5):678-683. PubMed ID: 27865034
[TBL] [Abstract][Full Text] [Related]
9. Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.
Pillai AA; Wedd J; Norvell JP; Parekh S; Cheng N; Young N; Spivey JR; Ford R
Am J Gastroenterol; 2016 Feb; 111(2):250-60. PubMed ID: 26832650
[TBL] [Abstract][Full Text] [Related]
10. Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.
Jackson WE; Hanouneh M; Apfel T; Alkhouri N; John BV; Zervos X; Zein NN; Hanouneh IA
Clin Transplant; 2016 Jun; 30(6):709-13. PubMed ID: 27019204
[TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.
Faisal N; Bilodeau M; Aljudaibi B; Hirsch G; Yoshida EM; Hussaini T; Ghali MP; Congly SE; Ma MM; Leonard J; Cooper C; Peltekian K; Renner EL; Lilly LB
Transplantation; 2016 May; 100(5):1059-65. PubMed ID: 26950722
[TBL] [Abstract][Full Text] [Related]
12. A systematic review with meta-analysis: Is ribavirin necessary in sofosbuvir-based direct-acting antiviral therapies for patients with HCV recurrence after liver transplantation?
Xue W; Liu K; Qiu K; Shen Y; Pan Z; Hu P; Peng M; Chen M; Ren H
Int J Infect Dis; 2019 Jun; 83():56-63. PubMed ID: 30959250
[TBL] [Abstract][Full Text] [Related]
13. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
Wyles D; Pockros P; Morelli G; Younes Z; Svarovskaia E; Yang JC; Pang PS; Zhu Y; McHutchison JG; Flamm S; Lawitz E
Hepatology; 2015 Jun; 61(6):1793-7. PubMed ID: 25846014
[TBL] [Abstract][Full Text] [Related]
14. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
Grant JL; Hawkins C; Brooks H; Palella FJ; Koppe SW; Abecassis MM; Stosor V
AIDS; 2016 Jan; 30(1):93-8. PubMed ID: 26731756
[TBL] [Abstract][Full Text] [Related]
15. Course of hepatitis C virus (HCV) RNA and HCV core antigen testing are predictors for reaching sustained virologic response in liver transplant recipients undergoing sofosbuvir treatment in a real-life setting.
Pischke S; Polywka S; Proske VM; Lang M; Jordan S; Nashan B; Lohse AW; Sterneck M
Transpl Infect Dis; 2016 Feb; 18(1):141-5. PubMed ID: 26485543
[TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.
Dumortier J; Leroy V; Duvoux C; de Ledinghen V; Francoz C; Houssel-Debry P; Radenne S; d'Alteroche L; Fougerou-Leurent C; Canva V; di Martino V; Conti F; Kamar N; Moreno C; Lebray P; Tran A; Besch C; Diallo A; Rohel A; Rossignol E; Abergel A; Botta-Fridlund D; Coilly A; Samuel D; Duclos-Vallée JC; Pageaux GP
Liver Transpl; 2016 Oct; 22(10):1367-78. PubMed ID: 27348086
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
Leroy V; Dumortier J; Coilly A; Sebagh M; Fougerou-Leurent C; Radenne S; Botta D; Durand F; Silvain C; Lebray P; Houssel-Debry P; Kamar N; D'Alteroche L; Petrov-Sanchez V; Diallo A; Pageaux GP; Duclos-Vallee JC;
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1993-2001.e1-2. PubMed ID: 26044317
[TBL] [Abstract][Full Text] [Related]
18. Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs.
Hartman J; Bichoupan K; Patel N; Chekuri S; Harty A; Dieterich D; Perumalswami P; Branch AD
World J Gastroenterol; 2015 Nov; 21(43):12430-8. PubMed ID: 26604650
[TBL] [Abstract][Full Text] [Related]
19. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.
Brown RS; O'Leary JG; Reddy KR; Kuo A; Morelli GJ; Burton JR; Stravitz RT; Durand C; Di Bisceglie AM; Kwo P; Frenette CT; Stewart TG; Nelson DR; Fried MW; Terrault NA;
Liver Transpl; 2016 Jan; 22(1):24-33. PubMed ID: 26519873
[TBL] [Abstract][Full Text] [Related]
20. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.
Pungpapong S; Aqel B; Leise M; Werner KT; Murphy JL; Henry TM; Ryland K; Chervenak AE; Watt KD; Vargas HE; Keaveny AP
Hepatology; 2015 Jun; 61(6):1880-6. PubMed ID: 25722203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
